Organizations that delay systematic AI deployment risk being left behind by competitors who have already mastered the transition from experimentation to execution.

Novartis and ProFound Therapeutics have entered into a four-year partnership aimed at discovering and developing new ...

ProFound Therapeutics enters multi-year strategic collaboration with Novartis to discover and develop novel therapeutics for cardiovascular disease: Cambridge, Massachusetts Frida ...

Using the ProFoundry platform and Novartis' expertise, the partners will identify novel proteins and drug targets for cardiovascular disease.

Cambridge, USA-based ProFound Therapeutics today announced a four-year collaboration with Swiss pharma giant Novartis to ...

Novartis is penning a four-year pact with ProFound Therapeutics to create new therapeutics for heart disease, with $750 ...

Obesity is a global health crisis with profound clinical and societal consequences, contributing to increased risks of ...

Novartis will present data from 60 company or investigator sponsored abstracts that have the potential to change clinical practice, at the 2025 American Society of Clinical Oncology (ASCO) Annual ...

Novartis in oncology The Novartis oncology strategy focuses on people living with cancer and those who care for them, from loved ones to clinical care teams, including their providers. For the past ...

In 2022, Novartis said it would cut 8,000 jobs globally, Reuters reported, a move that would save the company $1 billion over the next two years. Additionally, the company spun off its generics ...

In an era where sustainability and economic resilience are more important than ever, International Process Plants (IPP) is leading the charge in industrial redevelopment. One of its most ambitious ...